VANDERBILT UNIVERSITY MEDICAL CENTER

• WASHINGTON UNIVERSITY, THE

  UEI L6NFUM28LQM5

  $5.9M

  Subcontractor to this prime · 3 sub-awards · latest Oct 31, 2024

  • Centers for Disease Control and Prevention
  • “SCOPE OF WORK - VUMC THE OVERALL PURPOSE OF THE PROJECT INCLUDES THE FOLLOWING 4 TASKS: DESIGN A MULTI-SITE STUDY OF INFLUENZA TRANSMISSION WITHIN HOUSEHOLDS, ENROLL ELIGIBLE HOUSEHOLDS AND CONDUCT PROSPECTIVE STUDY ACTIVITIES, CONDUCT LABORATORY STUDIES TO CHARACTERIZE SUSCEPTIBILITY AND INFECTION, AND, PROVIDE DATA MANAGEMENT FOR SITUATIONAL AWARENESS AND ANALYSES. TO ACCOMPLISH THE PROJECT€„¢S OBJECTIVES, OUR VUMC SITE WILL ENROLL AND FOLLOW APPROXIMATELY 150 HOUSEHOLDS. VUMC WILL SERVE AS A SUBCONTRACTOR TO WASHINGTON UNIVERSITY AND WILL SERVE AS THE DATA COORDINATING CENTER (DCC) AND CENTRAL VIRAL LABORATORY FOR THE NETWORK. TO ENSURE EFFECTIVE AND EFFICIENT IDENTIFICATION OF INDEX CASES, REGARDLESS OF PRESENCE OF SYMPTOMS AND RAPID ENROLMENT AND COMPLETE FOLLOW-UP OF INDEX CASES AND HOUSEHOLD CONTACTS, WE WILL IMPLEMENT A MODIFIED CASE-ASCERTAINED STUDY DESIGN. WE WILL USE ESTABLISHED HIGH-THROUGHPUT STATE-OF-THE-ART TESTING PLATFORMS TO ACCURATELY IDENTIFY INFLUENZA INFECTIONS AND APPLY A DETAILED ALGORITHM TO DETERMINE AND VERIFY VACCINATION HISTORY. IN ADDITION, WE WILL IMPLEMENT AN INTEGRATED DATA SYSTEM FOR COLLECTION AND MANAGEMENT OF ALL STUDY ELEMENTS, THAT ENSURES REAL-TIME DATA SHARING.”
  • “SCOPE OF WORK C.1 BACKGROUND AND NEED THE SUBCONTRACTOR WILL BE VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) (NASHVILLE, TENNESSEE, USA). VUMC IS A NON-PROFIT 501(C) (3) HOSPITAL INCORPORATED IN THE STATE OF TENNESSEE. THE US ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) RECOMMENDS ANNUAL INFLUENZA VACCINATION FOR THOSE 6 MONTHS OLD OR OLDER. WHILE PRIOR INFLUENZA VACCINE EFFECTIVENESS (VE) STUDIES HAVE EVALUATED PREVENTION OF DISEASE IN DIFFERENT HEALTHCARE SETTINGS, THE IMPACT OF THESE VACCINES IN PREVENTING TRANSMISSION OF INFECTION REMAINS UNDERSTUDIED. MOREOVER, THE ONGOING STUDIES CONDUCTED DURING THE SARS-COV-2 PANDEMIC HAVE DOCUMENTED THAT THE RISK OF SECONDARY INFECTIONS IN HOUSEHOLDS HAVE BEEN CONSISTENTLY HIGHER THAN THOSE MEASURED WITH SIMILAR METHODOLOGIES PRIOR TO THE START OF THE PANDEMIC. THE IMPACT OF THOSE CHANGES IN TRANSMISSION RISK ON THE EFFECTIVENESS OF INFLUENZA VACCINES FOR PREVENTING TRANSMISSION REMAINS UNCLEAR. THE GOAL OF THIS STUDY IS TO ASCERTAIN SECONDARY INFECTION RISKS AND CONDUCT A ROBUST MULTI-CENTER EVALUATION OF INFLUENZA VE IN PREVENTING LABORATORY-CONFIRMED INFECTION TRANSMISSION IN HOUSEHOLDS. WE WILL PARTICIPATE IN COMPLETING ALL AIMS OUTLINED FOR THIS APPLICATION. WE WILL PARTICIPATE IN THE DESIGN AND ASSEMBLY OF A NETWORK OF 3 US RESEARCH SITES AND SERVE AS AN ENROLLING SITE AND AS THE DATA AND LABORATORY COORDINATING CENTER FOR THE NETWORK. WE WILL PARTICIPATE IN THE DESIGN AND EXECUTION OF A CASE-ASCERTAINED STUDY WITH DAILY COLLECTION OF DATA AND SPECIMENS TO ASSESS THE TRANSMISSION OF INFLUENZA INFECTIONS AND THE EFFECTIVENESS OF VACCINATION IN PREVENTING SUSCEPTIBILITY AND INFECTIVITY. WE WILL ALSO PARTICIPATE IN EXAMINING THE ROLE OF THERAPEUTICS, ISOLATION AND QUARANTINE ON THE FREQUENCY OF SECONDARY INFECTIONS IN HOUSEHOLDS. WE WILL HELP CHARACTERIZE IN DETAIL THE CLINICAL AND VIROLOGICAL COURSE OF SYMPTOMATIC, ASYMPTOMATIC AND PAUCI-SYMPTOMATIC INFECTIONS. OUR STUDY WILL BE LED BY INVESTI”
• THE JOHNS HOPKINS UNIVERSITY

  UEI FTMTDMBR29C7

  $801.6K

  Subcontractor to this prime · 1 sub-award · latest Mar 24, 2025

  • National Institutes of Health
  • “THE CONTRACTOR SHALL PERFORM A PHASE I CLINICAL STUDY TO EVALUATE INFECTIVITY, SAFETY, AND IMMUNOGENICITY OF A SINGLE INTRANASAL DOSE OF THE RECOMBINANT BIVALENT LIVE-ATTENUATED HPIV3/HMPV VACCINES B/HPIV3/HMPV-PREF-A AND B/HPIV3/HMPV-FB-DS365 SERONEGATIVE CHILDREN AND INFANTS.”
• UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  UEI NMJHD63STRC5

  $750K

  Subcontractor to this prime · 1 sub-award · latest Nov 19, 2024

  • National Institutes of Health
  • “CENTER FOR INFLUENZA VACCINE RESEARCH FOR HIGH RISK POPULATIONS”
• UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  UEI MKAGLD59JRL1

  $703.8K

  Subcontractor to this prime · 1 sub-award · latest Apr 20, 2026

  • Defense Health Agency
  • “OPEN LABEL, MULTI-CENTER, PREHOSPITAL RANDOMIZED TRIAL TO DETERMINE WHETHER PREHOSPITAL LOW TITER WHOLE BLOOD AS COMPARED TO STANDARD PREHOSPITAL RESUSCITATION RESULTS IN LOWER 30-DAY MORTALITY IN PATIENTS.”

• UNIVERSITY OF WASHINGTON

  UEI HD1WMN6945W6 · not in the directory yet

  $3.6M

  Subcontracted by this company · 2 sub-awards · latest Jul 11, 2024

  • Centers for Disease Control and Prevention
  • “"IVY 5 - SURVEILLANCE OF ACUTELY ILL ADULTS WITH RESPIRATORY VIRUSES, INCLUDING SARS-COV-2 "”
  • “A NEW NETWORK OF HOUSEHOLD TRANSMISSION STUDIES FOR VACCINE EFFECTIVENESS EVALUATIONS”
• OREGON HEALTH & SCIENCE UNIVERSITY

  UEI NPSNT86JKN51 · not in the directory yet

  $1.4M

  Subcontracted by this company · 2 sub-awards · latest Aug 12, 2024

  • Centers for Disease Control and Prevention

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.